Stock Movers: Fannie Mae & Freddie Mac, Sweetgreen, Under Armour

The Trump administration is reportedly considering selling 5-15% of Fannie Mae and Freddie Mac shares, potentially raising $30 billion and valuing the entities at over $500 billion, which sent their shares surging up to 22%. Concurrently, Gilead Sciences lifted its full-year outlook following strong second-quarter HIV drug sales that modestly beat expectations. Conversely, Under Armour shares plummeted as much as 21% after forecasting worse-than-expected sales and profit for the current quarter, indicating a significant setback in its turnaround efforts.

Analysis

The market is witnessing significant divergence driven by company-specific catalysts. Fannie Mae (FNMA) and Freddie Mac (FMCC) experienced a substantial rally, with shares surging as much as 22%, following reports that the Trump administration is considering a partial privatization. This plan could involve selling a 5% to 15% stake in the government-controlled mortgage giants, potentially raising $30 billion and valuing the firms at over $500 billion, though no final decision has been made. In the healthcare sector, Gilead Sciences (GILD) demonstrated fundamental strength by raising its full-year outlook after its second-quarter revenue and earnings, fueled by strong HIV drug sales, modestly beat analyst expectations. The company lifted its profit forecast to as much as $8.25 per share from a prior $8.10. Conversely, Under Armour (UAA) saw its turnaround narrative stall, with its stock plummeting as much as 21%. The athletic-wear brand projected a 6% to 7% revenue decline for its second quarter, a significantly worse outlook than the 3% drop analysts had anticipated, compounding an already challenging year where the stock had declined nearly 20% year-to-date.

Key Decisions for Investors

• Investors should monitor for concrete administrative actions regarding the potential share offering for Fannie Mae and Freddie Mac, as the significant upside is currently balanced by substantial political and execution uncertainty.
• Gilead's upward revision in its full-year guidance, driven by its core HIV franchise, reinforces a positive fundamental outlook, suggesting that the company's operational performance is improving.
• Under Armour's severe downward revision of its sales forecast, which is more than double the consensus expectation, signals a significant disruption to its turnaround narrative, warranting a re-evaluation of any long positions and a cautious approach until signs of stabilization emerge.